Alteration of cyclic nucleotide levels in phorbol 12-myristate 13-acetate treated myoblasts.
D015124:8-Bromo Cyclic Adenosine Monophosphate; D000628:Aminophylline / Q000494:pharmacology; D000818:Animals; D001693:Biological Transport, Active / Q000187:drug effects; D002478:Cells, Cultured; D002642:Chick Embryo; D000242:Cyclic AMP / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D006152:Cyclic GMP / Q000031:analogs & derivatives / Q000378:metabolism* / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D003847:Deoxyglucose / Q000378:metabolism; D007700:Kinetics; D009132:Muscles / Q000187:drug effects / Q000196:embryology / Q000378:metabolism*; D010704:Phorbols / Q000494:pharmacology*; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology*; D013806:Theophylline / Q000494:pharmacology
D010704:Phorbols; D003609:Dactinomycin; D015124:8-Bromo Cyclic Adenosine Monophosphate; D000628:Aminophylline; C016276:8-bromocyclic GMP; D003513:Cycloheximide; D003847:Deoxyglucose; D013806:Theophylline; D000242:Cyclic AMP; D006152:Cyclic GMP; D013755:Tetradecanoylphorbol Acetate